
  
    
      
        
        RNA_NNP interference_NN (_( RNAi_NNP )_) has_VBZ been_VBN called_VBN “ one_CD of_IN the_DT most_JJS has_VBZ exciting_JJ discoveries_NNS in_IN
        biology_NN in_IN the_DT last_JJ couple_NN decades_NNS ,_,” and_CC since_IN it_PRP was_VBD first_RB recognized_VBN by_IN Andrew_NNP Fire_NNP et_CC
        al_NN ._. in_IN 1998_CD ,_, it_PRP has_VBZ quickly_RB become_VBN one_CD of_IN the_DT most_RBS powerful_JJ and_CC indispensable_JJ tools_NNS in_IN the_DT
        molecular_JJ biologist_NN 's_POS toolkit_NN ._. Using_VBG short_JJ double-stranded_JJ RNA_NNP (_( dsRNA_NN )_) molecules_NNS ,_, RNAi_NNP can_MD
        selectively_RB silence_VB essentially_RB any_DT gene_NN in_IN the_DT genome_NN ._. It_PRP is_VBZ an_DT ancient_JJ mechanism_NN of_IN gene_NN
        regulation_NN ,_, found_VBD in_IN eukaryotes_NNS as_RB diverse_JJ as_IN yeast_NN and_CC mammals_NNS ,_, and_CC probably_RB plays_VBZ a_DT
        central_JJ role_NN in_IN controlling_VBG gene_NN expression_NN in_IN all_DT eukaryotes_NNS ._. In_IN the_DT lab_NN ,_, RNAi_NNP is_VBZ
        routinely_RB used_VBN to_TO reveal_VB the_DT genetic_JJ secrets_NNS of_IN development_NN ,_, intracellular_NN signaling_VBG ,_,
        cancer_NN ,_, infection_NN ,_, and_CC a_DT full_JJ range_NN of_IN other_JJ phenomena_NNS ._. But_CC can_MD the_DT phenomenon_NN hailed_VBN by_IN
        the_DT journal_NN 
        Science_NNP as_IN the_DT “ Breakthrough_NNP of_IN the_DT Year_NN” in_IN 2002_CD break_VB out_IN of_IN the_DT lab_NN
        and_CC lead_VB to_TO novel_NN therapies_NNS as_RB well_RB ?_. Pharmaceutical_NNP giants_NNS are_VBP hoping_VBG so_RB ,_, and_CC several_JJ
        biotech_JJ companies_NNS have_VBP bet_VBN their_PRP$ futures_NNS on_IN it_PRP ,_, but_CC not_RB everyone_NN is_VBZ sanguine_JJ about_IN the_DT
        future_NN of_IN RNAi_NNP therapy_NN ._.
        At_IN the_DT heart_NN of_IN its_PRP$ promise_NN as_IN a_DT powerful_JJ therapeutic_JJ drug_NN lies_VBZ the_DT exquisite_JJ
        selectivity_NN of_IN RNAi_NNP :_: like_IN the_DT fabled_JJ “ magic_JJ bullet_NN ,_,” an_DT RNAi_NNP sequence_NN seeks_VBZ out_IN and_CC
        destroys_VBZ its_PRP$ target_NN without_IN affecting_VBG other_JJ genes_NNS ._. The_DT clinical_JJ applications_NNS appear_VBP
        endless_JJ :_: any_DT gene_NN whose_WP$ expression_NN contributes_VBZ to_TO disease_NN is_VBZ a_DT potential_JJ target_NN ,_, from_IN viral_JJ
        genes_NNS to_TO oncogenes_NNS to_TO genes_NNS responsible_JJ for_IN heart_NN disease_NN ,_, Alzheimer_NNP 's_POS disease_NN ,_, diabetes_NN ,_,
        and_CC more_JJR ._.
        But_CC for_IN all_DT its_PRP$ promise_NN ,_, RNAi_NNP therapy_NN is_VBZ a_DT long_JJ way_NN from_IN entering_VBG the_DT clinic_NN ._. While_IN it_PRP
        is_VBZ a_DT proven_VBN wunderkind_NN in_IN the_DT lab_NN ,_, to_TO date_NN no_DT tests_NNS have_VBP been_VBN done_VBN in_IN humans_NNS ,_, and_CC only_RB the_DT
        most_RBS modest_JJ and_CC circumscribed_JJ successes_NNS have_VBP been_VBN demonstrated_VBN in_IN animals_NNS ._. The_DT road_NN to_TO
        clinical_JJ success_NN is_VBZ littered_VBN with_IN great_JJ ideas_NNS that_WDT have_VBP come_VBN a_DT cropper_NN along_IN the_DT way_NN ,_,
        including_VBG two_CD other_JJ RNA-based_NNP therapies_NNS ,_, antisense_NN and_CC ribozymes_NNS ,_, both_DT of_IN which_WDT showed_VBD
        promise_NN at_IN the_DT bench_NN but_CC have_VBP largely_RB stumbled_VBN before_IN reaching_VBG the_DT bedside_NN ._. Is_VBZ RNAi_NNP also_RB
        likely_JJ to_TO fall_VB short_JJ ?_. Or_CC is_VBZ it_PRP different_JJ enough_RB to_TO make_VB this_DT third_JJ try_NN the_DT charm_NN ?_.
      
      
        Clinical_NNP Naïveté_NNP ,_, Mysterious_NNP Mechanisms_NNPS
        To_TO be_VB a_DT successful_JJ drug_NN ,_, a_DT molecule_NN must_MD overcome_VB a_DT long_RB set_NN of_IN hurdles_NNS ._. First_LS ,_, it_PRP must_MD
        be_VB able_JJ to_TO be_VB manufactured_VBN at_IN reasonable_JJ cost_NN and_CC administered_VBN safely_RB and_CC conveniently_RB ._.
        Then_RB ,_, and_CC even_RB more_RBR importantly_RB ,_, it_PRP must_MD be_VB stable_JJ enough_RB to_TO reach_VB its_PRP$ target_NN cells_NNS before_IN
        it_PRP is_VBZ degraded_JJ or_CC excreted_JJ ;_: it_PRP must_MD get_VB into_IN those_DT cells_NNS ,_, link_NN up_RB with_IN its_PRP$ intracellular_NN
        target_NN ,_, and_CC exert_VB its_PRP$ effect_NN ;_: and_CC it_PRP must_MD exert_VB enough_RB of_IN an_DT effect_NN to_TO improve_VB the_DT health_NN
        of_IN the_DT person_NN taking_VBG it_PRP ._. And_CC ,_, finally_RB ,_, it_PRP must_MD do_VB all_PDT this_DT without_IN causing_VBG significant_JJ
        toxic_JJ effects_NNS in_IN either_DT target_NN or_CC nontarget_NN tissues_NNS ._. No_DT matter_NN how_WRB good_JJ a_DT compound_NN looks_VBZ in_IN
        the_DT lab_NN ,_, if_IN it_PRP fails_VBZ to_TO clear_VB any_DT one_CD of_IN these_DT hurdles_NNS ,_, it_PRP is_VBZ useless_JJ as_IN a_DT drug_NN ._.
        For_IN RNA-based_NNP therapies_NNS ,_, manufacture_VB has_VBZ been_VBN seen_VBN as_IN a_DT soluble_JJ problem_NN ,_, while_IN delivery_NN ,_,
        stability_NN ,_, and_CC potency_NN have_VBP been_VBN the_DT most_RBS significant_JJ obstacles_NNS ._. “ There_EX was_VBD a_DT lot_NN of_IN
        clinical_JJ naïveté_NN” in_IN the_DT early_JJ days_NNS of_IN antisense_NN and_CC ribozymes_NNS ,_, according_VBG to_TO Nassim_NNP Usman_NNP ,_,
        Vice_NNP President_NNP for_IN Research_NNP and_CC Development_NNP at_IN Sirna_NNP Therapeutics_NNP in_IN Boulder_NNP ,_, Colorado_NNP ._.
        “ Compounds_NNP were_VBD pushed_VBN into_IN the_DT clinic_NN prematurely_RB ._.” Sirna_NNP began_VBD as_IN the_DT biotech_JJ startup_NN
        Ribozyme_NNP Pharmaceuticals_NNP ,_, which_WDT tried_VBD to_TO develop_VB ribozymes_NNS to_TO treat_VB several_JJ conditions_NNS ,_,
        including_VBG hepatitis_NNP C_NNP ._. A_DT ribozyme_NN is_VBZ an_DT RNA_NNP molecule_NN whose_WP$ sequence_NN and_CC structure_NN allow_VB it_PRP
        to_TO cleave_NN specific_JJ target_NN RNA_NNP molecules_NNS (_( see_VB Figure_NN 1_LS )_) ._. “ The_DT initial_JJ results_NNS with_IN hepatitis_NNP
        C_NNP were_VBD not_RB that_IN inspiring_JJ ,_,” says_VBZ Usman_NNP ,_, because_IN the_DT molecule_NN they_PRP used_VBD had_VBD low_JJ potency_NN and_CC
        a_DT short_JJ half-life_NN once_RB in_IN the_DT body_NN ._. Despite_IN “ enormous_JJ doses_NNS ,_,” the_DT viral_JJ load_NN was_VBD not_RB
        significantly_RB affected_VBN ._. “ It_PRP just_RB did_VBD n't_RB have_VB the_DT characteristics_NNS to_TO be_VB a_DT drug_NN ,_,” he_PRP says_VBZ ._. No_DT
        ribozyme_NN has_VBZ yet_RB been_VBN approved_VBN for_IN use_NN by_IN the_DT United_NNP States_NNPS Food_NNP and_CC Drug_NNP Administration_NNP
        (_( FDA_NNP )_) ._.
        Similarly_RB ,_, despite_IN much_JJ initial_JJ enthusiasm_NN ,_, attempts_VBZ to_TO develop_VB antisense_NN drugs_NNS have_VBP
        been_VBN largely_RB disappointing_JJ ._. Antisense_NNP is_VBZ a_DT single_JJ strand_NN of_IN RNA_NNP or_CC DNA_NNP ,_, complementary_JJ to_TO a_DT
        target_NN messenger_NN RNA_NNP (_( mRNA_NN )_) sequence_NN ;_: by_IN pairing_VBG up_RP with_IN it_PRP ,_, the_DT antisense_NN strand_NN prevents_VBZ
        translation_NN of_IN the_DT mRNA_NN (_( see_VB Figure_NN 2_LS )_) ._. At_IN least_JJS that_WDT was_VBD the_DT theory_NN ,_, and_CC early_JJ clinical_JJ
        results_NNS seemed_VBD to_TO support_VB the_DT theory_NN :_: antisense_NN drugs_NNS effectively_RB reduced_VBN tumor_NN sizes_NNS in_IN
        anticancer_NN trials_NNS and_CC viral_JJ loads_NNS in_IN antiviral_JJ trials_NNS ._. But_CC closer_JJR inspection_NN revealed_VBD these_DT
        results_NNS were_VBD largely_RB due_JJ to_TO an_DT increase_NN in_IN production_NN of_IN interferons_NNS by_IN the_DT immune_JJ system_NN
        in_IN response_NN to_TO high_JJ doses_NNS of_IN the_DT foreign_JJ RNA_NNP ,_, rather_RB than_IN to_TO specific_JJ silencing_VBG of_IN any_DT
        target_NN genes_NNS ._. (_( The_DT relatively_RB high_JJ proportion_NN of_IN C–G_NNP sequences_NNS in_IN antisense_NN mimics_VBZ
        bacterial_JJ and_CC viral_JJ genes_NNS ,_, thus_RB triggering_VBG the_DT immune_JJ response_NN ._. )_) When_WRB the_DT antisense_NN dose_NN
        was_VBD lowered_VBN to_TO prevent_VB the_DT interferon_NN response_NN ,_, the_DT clinical_JJ benefit_NN largely_RB disappeared_VBD as_RB
        well_RB ._. Thus_RB ,_, rather_RB than_IN being_VBG a_DT highly_RB specific_JJ therapy_NN ,_, antisense_NN seemed_VBD to_TO be_VB a_DT general_JJ
        immune_JJ system_NN booster_NN ._.
        But_CC as_RB long_RB as_IN patients_NNS were_VBD getting_VBG better_JJR ,_, does_VBZ it_PRP matter_VBP what_WP the_DT mechanism_NN was_VBD ?_. “ It_PRP
        does_VBZ n't_RB matter_VB if_IN you_PRP are_VBP a_DT patient_NN ,_, but_CC it_PRP does_VBZ matter_NN if_IN you_PRP are_VBP trying_VBG to_TO develop_VB the_DT
        next_JJ drug_NN ,_,” says_VBZ Cy_NNP Stein_NNP ,_, Associate_NNP Professor_NNP of_IN Medicine_NNP and_CC Pharmacology_NNP at_IN Columbia_NNP
        University_NNP College_NNP of_IN Physicians_NNPS and_CC Surgeons_NNP in_IN New_NNP York_NNP City_NNP ._. Stein_NNP has_VBZ researched_VBN
        antisense_NN for_IN more_JJR than_IN a_DT decade_NN ._. “ If_IN you_PRP get_VBP the_DT mechanism_NN wrong_JJ ,_, you_PRP 're_VBP not_RB going_VBG to_TO be_VB
        able_JJ to_TO do_VB it_PRP ._.”
        To_TO date_NN ,_, only_RB one_CD antisense_NN drug_NN has_VBZ received_VBN FDA_NNP approval_NN ._. Vitravene_NNP ,_, from_IN Isis_NNP
        Pharmaceuticals_NNP in_IN Carlsbad_NNP ,_, California_NNP ,_, is_VBZ used_VBN to_TO treat_VB cytomegalovirus_JJ infections_NNS in_IN the_DT
        eye_NN for_IN patients_NNS with_IN HIV_NNP ._. Vitravene_NNP is_VBZ actually_RB a_DT DNA_NNP antisense_NN drug_NN ,_, which_WDT binds_NNS to_TO viral_JJ
        DNA_NNP ,_, though_RB ,_, says_VBZ Usman_NNP ,_, “ it_PRP 's_VBZ unclear_JJ whether_IN it_PRP actually_RB works_VBZ by_IN an_DT antisense_NN
        mechanism_NN ._.” Stein_NNP expresses_VBZ a_DT similar_JJ skepticism_NN about_IN the_DT mechanism_NN of_IN a_DT second_JJ antisense_NN
        drug_NN ,_, Genasense_NNP ._. Genasense_NNP is_VBZ a_DT DNA-based_NNP treatment_NN that_IN targets_NNS Bcl-_NNP 2_CD ,_, a_DT protein_NN expressed_VBD
        in_IN high_JJ levels_NNS in_IN cancer_NN cells_NNS ,_, which_WDT is_VBZ thought_VBN to_TO protect_VB them_PRP from_IN standard_JJ
        chemotherapy_NN ._. The_DT FDA_NNP is_VBZ currently_RB reviewing_VBG an_DT application_NN for_IN Genasense_NNP ,_, based_VBN on_IN
        promising_JJ results_NNS in_IN the_DT treatment_NN of_IN malignant_JJ melanoma_NN ._.
      
      
        RNAi_NNP :_: A_DT Natural_NNP Alternative_NNP
        Growing_VBG disillusionment_NN with_IN antisense_NN and_CC ribozymes_NNS coincided_VBD with_IN the_DT discovery_NN of_IN
        RNAi_NNP and_CC the_DT realization_NN that_IN it_PRP was_VBD a_DT far_RB more_RBR potent_JJ way_NN to_TO silence_VB gene_NN expression_NN ._. RNAi_NNP
        uses_VBZ short_JJ dsRNA_NN molecules_NNS whose_WP$ sequence_NN matches_VBZ that_IN of_IN the_DT gene_NN of_IN interest_NN ._. Once_RB in_IN a_DT
        cell_NN ,_, a_DT dsRNA_NN molecule_NN is_VBZ cleaved_JJ into_IN segments_NNS approximately_RB 22_CD nucleotides_NNS long_JJ ,_, called_VBD
        short_JJ interfering_VBG RNAs_NNP (_( siRNAs_NNS )_) (_( see_VB Figure_NN 3_LS )_) ._. siRNAs_NNS become_VBP bound_VBN to_TO the_DT RNA-induced_NNP
        silencing_VBG complex_JJ (_( RISC_NNP )_) ,_, which_WDT then_RB also_RB binds_NNS any_DT matching_VBG mRNA_NN sequence_NN ._. Once_RB this_DT
        occurs_VBZ ,_, the_DT mRNA_NN is_VBZ degraded_JJ ,_, effectively_RB silencing_VBG the_DT gene_NN from_IN which_WDT it_PRP came_VBD ._. (_( Details_NNS
        of_IN the_DT structure_NN and_CC function_NN of_IN the_DT RISC_NNP are_VBP still_RB largely_RB unknown_JJ ,_, but_CC it_PRP is_VBZ thought_VBN to_TO
        act_VB as_IN a_DT true_JJ enzyme_NN complex_JJ ,_, requiring_VBG only_RB one_CD or_CC several_JJ siRNA_NN molecules_NNS to_TO degrade_NN many_JJ
        times_NNS that_WDT number_NN of_IN matching_VBG mRNAs_NNS ._. )_)
        The_DT extraordinary_JJ selectivity_NN of_IN RNAi_NNP ,_, combined_VBN with_IN its_PRP$ potency—in_NN theory_NN ,_, only_RB a_DT few_JJ
        dsRNAs_NNS are_VBP needed_VBN per_IN cell—quickly_RB made_VBN it_PRP the_DT tool_NN of_IN choice_NN for_IN functional_JJ genomics_NNS
        (_( determining_VBG what_WP a_DT gene_NN product_NN does_VBZ and_CC with_IN what_WP other_JJ products_NNS it_PRP interacts_NNS )_) and_CC for_IN
        drug_NN target_NN discovery_NN and_CC validation_NN ._. By_IN “ knocking_VBG down_RP” a_DT gene_NN with_IN RNAi_NNP and_CC determining_VBG
        how_WRB a_DT cell_NN responds_VBZ ,_, a_DT researcher_NN can_MD ,_, in_IN the_DT course_NN of_IN only_RB a_DT few_JJ days_NNS ,_, develop_VB
        significant_JJ insight_NN into_IN the_DT function_NN of_IN the_DT gene_NN and_CC determine_VB whether_IN reducing_VBG its_PRP$
        expression_NN is_VBZ likely_JJ to_TO be_VB therapeutically_RB useful_JJ ._. But_CC does_VBZ RNAi_NNP have_VB a_DT better_JJR chance_NN to_TO
        succeed_VB as_IN a_DT drug_NN than_IN antisense_NN or_CC ribozymes_NNS ?_.
        “ The_DT fundamental_JJ difference_NN favoring_VBG RNAi_NNP is_VBZ that_IN we_PRP 're_VBP harnessing_VBG an_DT endogenous_JJ ,_,
        natural_JJ pathway_NN ,_,” says_VBZ Nagesh_NNP Mahanthappa_NNP ,_, Director_NNP of_IN Corporate_NNP Development_NNP at_IN Alnylam_NNP
        Pharmaceuticals_NNP in_IN Cambridge_NNP ,_, Massachusetts_NNP ,_, the_DT second_NN of_IN two_CD major_JJ biotech_JJ company_NN
        developing_VBG RNAi-based_NNP therapy_NN ._. The_DT exploitation_NN of_IN a_DT pre-existing_JJ mechanism_NN ,_, he_PRP says_VBZ ,_, is_VBZ
        the_DT main_JJ reason_NN RNAi_NNP is_VBZ orders_NNS of_IN magnitude_NN more_RBR potent_JJ than_IN either_DT of_IN the_DT other_JJ two_CD types_NNS
        of_IN RNA_NNP strategies_NNS ._.
      
      
        Delivery_NN ,_, Delivery_NN ,_, Delivery_NN
        More_RBR potent_JJ in_IN the_DT test_NN tube_NN ,_, at_IN least_JJS ._. But_CC stability_NN and_CC delivery_NN are_VBP also_RB the_DT major_JJ
        obstacles_NNS to_TO successful_JJ RNAi_NNP therapy_NN ,_, obstacles_NNS that_WDT are_VBP intrinsic_JJ to_TO the_DT biochemical_JJ
        nature_NN of_IN RNA_NNP itself_PRP ,_, as_RB well_RB as_IN the_DT body_NN 's_POS defenses_NNS against_IN infection_NN with_IN foreign_JJ
        nucleotides_NNS ._. “ For_IN the_DT strongest_JJS reasons_NNS ,_, you_PRP ca_MD n't_RB get_VB away_RB from_IN this_DT ,_,” says_VBZ Stein_NNP ._. “ The_DT
        problem_NN is_VBZ that_IN a_DT charged_VBN oligonucleotide_NN will_MD not_RB pass_VB through_IN a_DT lipid_NN layer_NN ,_,” which_WDT it_PRP
        must_MD do_VB in_IN order_NN to_TO enter_VB a_DT cell_NN ._. John_NNP Rossi_NNP ,_, Director_NNP of_IN the_DT Department_NNP of_IN Molecular_NNP
        Biology_NNP at_IN City_NNP of_IN Hope_NNP Hospital_NNP in_IN Duarte_NNP ,_, California_NNP ,_, who_WP has_VBZ worked_VBN on_IN RNA-based_NNP
        therapies_NNS for_IN 15_CD years_NNS ,_, concurs_NNS ._. “ The_DT cell_NN does_VBZ n't_RB want_VB to_TO take_VB up_RP RNA_NNP ,_,” he_PRP says_VBZ ,_, which_WDT
        makes_VBZ evolutionary_JJ sense_NN ,_, since_IN extracellular_NN RNA_NNP usually_RB signifies_NNS a_DT viral_JJ infection_NN ._.
        Injected_NNP into_IN the_DT bloodstream_NN ,_, unmodified_JJ RNA_NNP is_VBZ rapidly_RB excreted_JJ by_IN the_DT kidneys_NNS or_CC
        degraded_JJ by_IN enzymes_NNS ._.
        To_TO solve_VB the_DT problem_NN of_IN cell_NN penetration_NN ,_, most_JJS researchers_NNS have_VBP either_CC complexed_JJ the_DT RNA_NNP
        with_IN a_DT lipid_NN or_CC modified_VBN the_DT RNA_NNP 's_POS phosphate_NN backbone_NN to_TO minimize_VB its_PRP$ charge_NN ._. Mahanthappa_NNP
        thinks_VBZ the_DT complexing_VBG approach_NN is_VBZ unlikely_JJ to_TO be_VB a_DT simple_JJ solution_NN ,_, since_IN drug_NN approval_NN
        would_MD require_VB independent_JJ testing_NN of_IN the_DT lipid_NN delivery_NN system_NN as_RB well_RB ._. Instead_RB ,_, Alnylam_NNP is_VBZ
        pursuing_VBG backbone_NN modification_NN ._. “ Some_DT minimal_JJ modification_NN is_VBZ going_VBG to_TO be_VB necessary_JJ” to_TO
        increase_VB cell_NN uptake_NN and_CC to_TO improve_VB stability_NN in_IN the_DT blood_NN stream_NN ,_, Mahanthappa_NNP says_VBZ ._. “ What_WP
        we_PRP have_VBP learned_VBN from_IN the_DT antisense_NN field_NN is_VBZ that_IN even_RB without_IN other_JJ delivery_NN strategies_NNS ,_,
        when_WRB you_PRP administer_VB RNA_NNP at_IN sufficient_JJ doses_NNS ,_, if_IN it_PRP 's_VBZ stable_JJ ,_, it_PRP gets_VBZ taken_VBN up_RP by_IN
        cells_NNS ._.”
        “ Anything_NN that_WDT can_MD be_VB done_VBN to_TO increase_VB half-life_NN in_IN circulation_NN would_MD improve_VB delivery_NN ,_,”
        says_VBZ Judy_NNP Lieberman_NNP ,_, a_DT Senior_NNP Investigator_NNP at_IN the_DT Center_NNP for_IN Blood_NNP Research_NNP and_CC Associate_NNP
        Professor_NNP of_IN Pediatrics_NNP at_IN Harvard_NNP Medical_NNP School_NNP in_IN Cambridge_NNP ,_, Massachusetts_NNP ._. But_CC that_DT may_MD
        not_RB be_VB the_DT only_JJ problem_NN ,_, she_PRP cautions_VBZ ._. Lieberman_NNP 's_POS lab_NN recently_RB demonstrated_VBD the_DT ability_NN of_IN
        RNAi_NNP to_TO silence_VB expression_NN of_IN the_DT Fas_NNP gene_NN in_IN mice_NNS ,_, protecting_VBG them_PRP from_IN fulminant_NN
        hepatitis_NN ._. Fas_NNP triggers_VBZ apoptosis_NNS ,_, or_CC programmed_VBN cell_NN death_NN ,_, in_IN response_NN to_TO a_DT variety_NN of_IN
        cell_NN insults_NNS ._. In_IN her_PRP$ experiment_NN ,_, Lieberman_NNP delivered_VBD the_DT RNA_NNP by_IN high-pressure_JJ injection_NN
        into_IN the_DT tail_NN ._. The_DT RNA_NNP got_VBD to_TO the_DT liver_NN ,_, silenced_VBN Fas_NNP ,_, and_CC protected_VBD the_DT mice_NNS from_IN
        hepatitis_NN ._. However_RB ,_, a_DT significant_JJ fraction_NN of_IN animals_NNS died_VBD of_IN heart_NN failure_NN ,_, brought_VBN on_IN
        because_IN the_DT injection_NN volume_NN was_VBD about_IN 20_CD %_NN of_IN the_DT mouse_NN blood_NN volume_NN ._. Such_JJ a_DT delivery_NN
        scheme_NN simply_RB will_MD not_RB work_VB in_IN humans_NNS ._. “ Delivery_NN to_TO the_DT cell_NN is_VBZ still_RB an_DT obstacle_NN ,_,”
        Lieberman_NNP explains_VBZ ._. “ Unless_IN you_PRP really_RB focus_VBP on_IN how_WRB to_TO solve_VB that_DT problem_NN ,_, you_PRP 're_VBP not_RB going_VBG
        to_TO get_VB very_RB far_RB ._.”
      
      
        Unanswered_NNP Questions_NNS
        Even_RB assuming_VBG delivery_NN problems_NNS can_MD be_VB solved_VBN ,_, other_JJ questions_NNS remain_VBP ,_, including_VBG that_IN of_IN
        whether_IN therapeutic_JJ levels_NNS of_IN RNAi_NNP may_MD be_VB toxic_JJ ._. Mahanthappa_NNP says_VBZ ,_, “ The_DT conservative_JJ answer_NN
        is_VBZ we_PRP just_RB do_VBP n't_RB know_VB ._. The_DT more_RBR aggressive_JJ answer_NN is_VBZ there_EX 's_VBZ no_DT reason_NN to_TO think_VB so_RB ._.” Rossi_NNP
        is_VBZ n't_RB so_RB sure_JJ ._. “ The_DT target_NN of_IN interest_NN may_MD be_VB in_IN normal_JJ cells_NNS as_RB well_RB as_IN cancer_NN cells_NNS ,_,” he_PRP
        says_VBZ ._. “ That_DT 's_VBZ where_WRB you_PRP get_VBP toxicity_NN ._.”
        But_CC if_IN small_JJ RNAs_NNP can_MD be_VB delivered_VBN to_TO target_VB cells_NNS efficiently_RB and_CC without_IN significant_JJ
        toxicity_NN ,_, will_MD they_PRP be_VB effective_JJ medicines_NNS ?_. Usman_NNP of_IN Sirna_NNP is_VBZ confident_JJ they_PRP will_MD be_VB ._. “ If_IN
        you_PRP can_MD get_VB it_PRP there_RB ,_, and_CC if_IN it_PRP 's_VBZ in_IN one_CD piece_NN ,_, there_EX no_DT doubt_NN in_IN our_PRP$ minds_NNS that_IN it_PRP will_MD
        work_VB ,_,” he_PRP says_VBZ ._. To_TO date_NN ,_, numerous_JJ experiments_NNS in_IN animal_NN models_NNS suggest_VBP RNAi_NNP can_MD
        downregulate_NN a_DT variety_NN of_IN target_NN genes_NNS effectively_RB ._. However_RB ,_, there_EX are_VBP still_RB two_CD unanswered_JJ
        questions_NNS about_IN whether_IN that_DT will_MD translate_VB into_IN effective_JJ therapy_NN ._.
        The_DT first_JJ is_VBZ whether_IN RNAi_NNP 's_POS exquisite_JJ specificity_NN is_VBZ really_RB an_DT advantage_NN beyond_IN the_DT
        bench_NN ._. “ It_PRP 's_VBZ unclear_JJ whether_IN highly_RB specific_JJ drugs_NNS give_VBP you_PRP a_DT big_JJ therapeutic_JJ effect_NN ,_,” says_VBZ
        Cy_NNP Stein_NNP ._. For_IN instance_NN ,_, he_PRP says_VBZ ,_, “ most_RBS active_JJ antitumor_NN medicines_NNS have_VBP multiple_JJ mechanisms_NNS
        of_IN action_NN ._. The_DT more_RBR specific_JJ you_PRP make_VBP it_PRP ,_, the_DT less_RBR robust_JJ the_DT therapeutic_JJ activity_NN is_VBZ
        likely_JJ to_TO be_VB ._.” Rossi_NNP agrees_VBZ :_: “ Overspecificity_NNP has_VBZ never_RB worked_VBN ,_,” he_PRP says_VBZ ._.
        The_DT second_JJ question_NN is_VBZ what_WP effect_NN an_DT excess_NN of_IN RNA_NNP from_IN outside_IN the_DT cell_NN will_MD have_VB on_IN
        the_DT normal_JJ function_NN of_IN the_DT RISC_NNP ,_, the_DT complex_NN at_IN the_DT heart_NN of_IN the_DT RNAi_NNP mechanism_NN ._. The_DT number_NN
        of_IN RISCs_NNP in_IN the_DT cell_NN is_VBZ unknown_JJ ,_, and_CC one_CD concern_NN is_VBZ that_IN the_DT amount_NN of_IN RNA_NNP needed_VBD to_TO have_VB a_DT
        therapeutic_JJ effect_NN may_MD occupy_VB all_PDT the_DT available_JJ complexes_NNS ._. “ We_PRP are_VBP usurping_VBG a_DT natural_JJ cell_NN
        system_NN that_WDT is_VBZ there_RB for_IN some_DT other_JJ purpose_NN ,_, for_IN knocking_VBG out_IN endogenous_JJ gene_NN function_NN ,_,”
        says_VBZ Rossi_NNP ._. With_IN the_DT introduction_NN of_IN foreign_JJ RNA_NNP ,_, will_MD the_DT system_NN continue_VB to_TO perform_VB its_PRP$
        normal_JJ function_NN as_IN well_RB ,_, or_CC will_MD it_PRP become_VB saturated_VBD ?_. “ That_DT 's_VBZ the_DT big_JJ black_JJ box_NN in_IN the_DT
        field_NN ,_,” he_PRP says_VBZ ._.
      
      
        Looking_VBG Ahead_NNP to_TO the_DT Clinic_NNP
        Despite_IN the_DT questions_NNS and_CC unsolved_JJ problems_NNS ,_, Sirna_NNP ,_, Alnylam_NNP ,_, and_CC several_JJ other_JJ companies_NNS
        are_VBP moving_VBG ahead_RB to_TO develop_VB RNAi_NNP therapy_NN ;_: indeed_RB ,_, some_DT outstanding_JJ questions_NNS are_VBP probably_RB
        only_RB likely_JJ to_TO be_VB answered_VBN in_IN the_DT process_NN of_IN therapeutic_JJ development_NN ._. The_DT first_JJ
        applications_NNS are_VBP likely_JJ to_TO be_VB in_IN cancer_NN (_( targeting_VBG out-of-control_JJ oncogenes_NNS )_) or_CC viral_JJ
        infection_NN (_( targeting_VBG viral_JJ genes_NNS )_) ._. To_TO avoid_VB some_DT of_IN the_DT problems_NNS of_IN delivery_NN ,_, initial_JJ
        trials_NNS may_MD deliver_VB the_DT RNA_NNP by_IN direct_JJ injection_NN into_IN the_DT target_NN tissue_NN (_( for_IN a_DT tumor_NN ,_, for_IN
        instance_NN )_) or_CC ex_FW vivo_NN ,_, treating_VBG white_JJ blood_NN cells_NNS infected_VBN with_IN HIV_NNP ,_, for_IN example_NN ._.
        Having_VBG spent_VBN a_DT decade_NN trying_VBG to_TO develop_VB ribozymes_NNS ,_, says_VBZ Usman_NNP ,_, Sirna_NNP is_VBZ prepared_VBN for_IN the_DT
        rough_JJ road_NN it_PRP faces_VBZ ._. “ We_PRP have_VBP n't_RB solved_VBN all_PDT the_DT problems_NNS ,_, but_CC we_PRP know_VBP how_WRB to_TO proceed_VB to_TO
        work_VB through_IN them_PRP ._. It_PRP 's_VBZ no_DT surprise_NN to_TO us—we_NN 've_VBP seen_VBN this_DT movie_NN before_RB ._.” Usman_NNP expects_VBZ
        Sirna_NNP to_TO file_VB an_DT Investigational_NNP New_NNP Drug_NNP Application_NNP with_IN the_DT FDA_NNP by_IN the_DT end_NN of_IN 2004_CD and_CC
        to_TO have_VB a_DT human_JJ clinical_JJ trial_NN in_IN progress_NN in_IN 2005_CD ._. “ Without_IN a_DT doubt_NN ,_, there_EX will_MD be_VB an_DT
        RNAi-based_NNP drug_NN within_IN ten_CD years_NNS ,_,” Usman_NNP predicts_VBZ ._.
        Stein_NNP is_VBZ n't_RB so_RB sure_JJ and_CC thinks_VBZ that_IN too_RB much_JJ is_VBZ still_RB to_TO be_VB learned_VBN about_IN RNAi_NNP and_CC the_DT
        body_NN 's_POS reaction_NN to_TO it_PRP to_TO be_VB confident_JJ that_IN RNA-based_NNP therapies_NNS will_MD ultimately_RB be_VB
        successful_JJ ._. “ The_DT whole_JJ field_NN was_VBD founded_VBN on_IN the_DT belief_NN it_PRP was_VBD rational_JJ ,_, but_CC there_EX are_VBP huge_JJ
        gaps_NNS in_IN our_PRP$ knowledge_NN ,_, and_CC so_IN you_PRP need_VBP a_DT bit_NN of_IN luck_NN to_TO be_VB successful_JJ ,_,” he_PRP says_VBZ ._. “ I_PRP think_VBP
        people_NNS are_VBP surprised_VBN at_IN how_WRB complicated_VBN it_PRP is_VBZ ,_, but_CC why_WRB should_MD it_PRP be_VB any_DT other_JJ way_NN ?_. It_PRP 's_VBZ an_DT
        intellectual_JJ conceit_NN to_TO think_VB that_DT nature_NN is_VBZ simple_JJ ._.”
      
    
  
